976 resultados para Family right


Relevância:

20.00% 20.00%

Publicador:

Resumo:

Left to Right: Ernest Goldschmidt, Ilse Goldschmidt born Molling, and Frank Goldschmidt. The picture was taken on the occasion of Ilse's 80th birthday party 22 Dec 1989 Laguna Hills, CA.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

From left to right: Lotte Stern, Otto Wallerstein, Alfred Stern; Photograph taken shortly after arrival in Berkeley, California

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Extreme lower right: Lotte Wallerstein

Relevância:

20.00% 20.00%

Publicador:

Resumo:

right: Joseph Molling sitting; left: unknown man standing

Relevância:

20.00% 20.00%

Publicador:

Resumo:

left unknown child; right Peter Molling

Relevância:

20.00% 20.00%

Publicador:

Resumo:

From left to right, standing: Ilse, Adolf, Grete and Lepold Meyerhof; from left to right, sitting: Joel Meyerhof and Therese Mayerhof nee Molling

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Front row from left to right: Walter, Ursula, and Freddy; back row from left to right: Hal, Elizabeth, and Kurt Godshaw; picture was probably taken in their backyard on Seelhorststrasse in Hannover, Germany

Relevância:

20.00% 20.00%

Publicador:

Resumo:

On shoulders left to right: Freddy, Walter; standing left to right: Kurt, Hal

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Background: The Ewing sarcoma family of tumors (ESFT) are rare but highly malignant neoplasms that occur mainly in bone or but also in soft tissue. ESFT affects patients typically in their second decade of life, whereby children and adolescents bear the heaviest incidence burden. Despite recent advances in the clinical management of ESFT patients, their prognosis and survival are still disappointingly poor, especially in cases with metastasis. No targeted therapy for ESFT patients is currently available. Moreover, based merely on current clinical and biological characteristics, accurate classification of ESFT patients often fails at the time of diagnosis. Therefore, there is a constant need for novel molecular biomarkers to be applied in tandem with conventional parameters to further intensify ESFT risk-stratification and treatment selection, and ultimately to develop novel targeted therapies. In this context, a greater understanding of the genetics and immune characteristics of ESFT is needed. Aims: This study sought to open novel insights into gene copy number changes and gene expression in ESFT and, further, to enlighten the role of inflammation in ESFT. For this purpose, microarrays were used to provide gene-level information on a genomewide scale. In addition, this study focused on screening of 9p21.3 deletion sizes and frequencies in ESFT and, in another pediatric cancer, acute lymphocytic leukemia (ALL), in order to define more exact criteria for highrisk patient selection and to provide data for developing a more reliable diagnostic method to detect CDKN2A deletions. Results: In study I, 20 novel ESFT-associated suppressor genes and oncogenes were pinpointed using combined array CGH and expression analysis. In addition, interesting chromosomal rearrangements were identified: (1) Duplication of derivative chromosome der(22)(11;22) was detected in three ESFT patients. This duplication included the EWSR1-FLI1 fusion gene leading to increase in its copy number; (2) Cryptic amplifications on chromosomes 20 and 22 were detected, suggesting a novel translocation between chromosomes 20 and 22, which most probably produces a fusion between EWSR1 and NFATC2. In study II, bioinformatic analysis of ESFT expression profiles showed that inflammatory gene activation is detectable in ESFT patient samples and that the activation is characterized by macrophage gene expression. Most interestingly, ESFT patient samples were shown to express certain inflammatory genes that were prognostically significant. High local expression of C5 and JAK1 at the tumor site was shown to associate with favorable clinical outcome, whereas high local expression of IL8 was shown to be detrimental. Studies III and IV showed that the smallest overlapping region of deletion in 9p21.3 includes CDKN2A in all cases and that the length of this region is 12.2 kb in both Ewing sarcoma and ALL. Furthermore, our results showed that the most widely used commercial CDKN2A FISH probe creates false negative results in the narrowest microdeletion cases (<190 kb). Therefore, more accurate methods should be developed for the detection of deletions in the CDKN2A locus. Conclusions: This study provides novel insights into the genetic changes involved in the biology of ESFT, in the interaction between ESFT cells and immune system, and in the inactivation of CDKN2A. Novel ESFT biomarker genes identified in this study serve as a useful resource for future studies and in developing novel therapeutic strategies to improve the survival of patients with ESFT.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Left to right: Ralph Grahme, Joan Grahme, Ilse Schuster nee Gottschalk, and James Schuster;